PortfoliosLab logo
Ampio Pharmaceuticals, Inc. (AMPE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US03209T1097

CUSIP

03209T109

IPO Date

Mar 31, 2010

Highlights

Market Cap

$908.00

EPS (TTM)

-$10.66

Target Price

$2.00

Short %

2.94%

Short Ratio

0.31

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Ampio Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%400.00%December2025FebruaryMarchAprilMay
-100.00%
381.54%
AMPE (Ampio Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period

Ampio Pharmaceuticals, Inc. (AMPE) returned 3.85% year-to-date (YTD) and -99.02% over the past 12 months. Over the past 10 years, AMPE returned -71.78% annually, underperforming the S&P 500 benchmark at 10.43%.


AMPE

YTD

3.85%

1M

350.00%

6M

170.00%

1Y

-99.02%

5Y*

-90.68%

10Y*

-71.78%

^GSPC (Benchmark)

YTD

-3.70%

1M

13.67%

6M

-5.18%

1Y

9.18%

5Y*

14.14%

10Y*

10.43%

*Annualized

Monthly Returns

The table below presents the monthly returns of AMPE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-19.23%-71.43%0.00%33.33%237.50%3.85%
2024-4.88%-20.51%-40.65%-72.72%-16.33%-47.62%-99.91%2,100.00%0.00%0.00%18.18%-0.00%-99.87%
202325.75%-7.80%-10.76%0.43%31.84%-24.47%-0.21%-15.70%-7.14%-32.17%133.28%-64.41%-54.48%
2022-9.19%-3.42%-5.98%-51.02%-20.59%-8.10%-9.52%-33.55%-40.10%-41.82%-21.78%-45.47%-97.37%
2021-1.26%8.92%-1.17%9.47%-2.16%-7.73%-15.57%16.31%1.22%-6.02%-27.56%-49.56%-64.15%
202019.38%-14.48%-30.28%46.60%-11.82%18.71%63.29%-31.15%33.66%-20.06%20.26%72.83%172.73%
201926.65%25.50%-10.44%1.39%-8.74%-25.42%0.23%27.96%0.74%-26.38%27.30%24.15%47.67%
2018-26.29%-26.00%53.15%-23.82%-29.73%20.88%35.00%-78.82%-19.24%-9.45%38.30%-37.94%-90.30%
20178.86%-16.33%-2.44%-30.11%56.63%-40.49%2.00%0.21%14.72%73.49%28.30%199.26%352.12%
2016-13.76%-10.50%5.63%87.11%-9.74%-66.05%-23.26%-16.49%-10.46%-7.27%10.72%18.45%-67.38%
201546.36%12.35%33.51%-67.99%-0.41%-1.25%13.08%9.70%-1.70%20.76%6.59%-5.91%2.04%
201419.50%-16.43%-10.81%-4.09%24.63%10.01%-27.78%-22.22%-24.73%9.92%-12.37%0.88%-51.89%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AMPE is 54, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AMPE is 5454
Overall Rank
The Sharpe Ratio Rank of AMPE is 5050
Sharpe Ratio Rank
The Sortino Ratio Rank of AMPE is 100100
Sortino Ratio Rank
The Omega Ratio Rank of AMPE is 100100
Omega Ratio Rank
The Calmar Ratio Rank of AMPE is 00
Calmar Ratio Rank
The Martin Ratio Rank of AMPE is 2222
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Ampio Pharmaceuticals, Inc. (AMPE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The current Ampio Pharmaceuticals, Inc. Sharpe ratio is -0.02. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Ampio Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00December2025FebruaryMarchAprilMay
-0.02
0.44
AMPE (Ampio Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Ampio Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-100.00%
-8.35%
AMPE (Ampio Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Ampio Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ampio Pharmaceuticals, Inc. was 100.00%, occurring on Jul 31, 2024. The portfolio has not yet recovered.

The current Ampio Pharmaceuticals, Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Oct 25, 20132704Jul 31, 2024
-83.33%Apr 5, 201035Jun 1, 2010135Jan 31, 2011170
-72.14%Sep 19, 2011166May 15, 2012363Oct 24, 2013529
-68%Mar 14, 20118Mar 23, 2011121Sep 14, 2011129
-20%Feb 16, 20112Feb 17, 20112Feb 22, 20114

Volatility

Volatility Chart

The current Ampio Pharmaceuticals, Inc. volatility is 301.99%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%100.00%200.00%300.00%400.00%500.00%600.00%December2025FebruaryMarchAprilMay
301.99%
11.43%
AMPE (Ampio Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Ampio Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Ampio Pharmaceuticals, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 12.1% positive surprise.


-2.50-2.00-1.50-1.00-0.500.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober
-2.48
-0.30
Actual
Estimate

Valuation

The Valuation section provides an overview of how Ampio Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for AMPE compared to other companies in the Biotechnology industry. AMPE currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AMPE relative to other companies in the Biotechnology industry. Currently, AMPE has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AMPE in comparison with other companies in the Biotechnology industry. Currently, AMPE has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items